Metabolomics - A 'systems' contribution to pharmaceutical discovery and drug development

Drug Discovery World

Volumn 7, Issue 2, 2006, Pages 39-46

  Harrigan, George G ^a  

^a MONSANTO COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; IMATINIB; NAPROXEN; NEW DRUG; PROTEOME; TRANSCRIPTOME;

ARTICLE; CANCER; CARDIOVASCULAR DISEASE; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG DETERMINATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DYSLIPIDEMIA; FINANCIAL MANAGEMENT; HIGH THROUGHPUT SCREENING; HUMAN; METABOLIC REGULATION; METABOLITE; METABOLOMICS; MITOCHONDRIAL RESPIRATION; NONHUMAN; PHARMACEUTICAL ENGINEERING; SIGNAL TRANSDUCTION;

EID: 33646233206     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Schmid, EF, Smith, DA. Is declining innovation in the pharmaceutical industry a myth? Drug Discovery Today 1, 1031-1039 (2005).
2. Mehta, V. Consolidation in the global biopharma sector. Genetic Engineering News 25, 48-49 (2005).
3. Harrigan, GG, Goodacre, R (Eds). Metabolic profiling: its role in biomarker discovery and gene function analysis. Kluwer Academic Publishers, MA, USA (2003).
4. Goodacre, R, Vaidyanathan, S, Dunn, WB, Harrigan, GG, Kell, DB. Metabolomics by numbers - acquiring and understanding global metabolite data.Trends Biotechnol. 22, 245-252 (2004).
5. Vaidyanathan, S, Harrigan, GG, Goodacre, R (Eds). Metabolome analyses: strategies for systems biology. Springer Science+Business Media, MA, USA (2005).
6. Hellerstein, MK. In vivo measurement of fluxes through metabolic pathways; the missing link in functional genomics and pharmaceutical research. Annu Rev Nutr 23, 379-402 (2003).
7. He, W, Miao, FJ-P, Lin, DC-H, Schwandner, RT, Wang, Z, Gao, J, Chen, J-L, Tian, H, Ling, L. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429, 188-193 (2004).
8. MacDonald, MJ, Fahlen, LA, Brown, LJ, Hasan, NM, Buss, JD, Kendrick, MA. Perspective: emerging evidence for signaling roles of mitochondrial products in insulin secretion. Am J. Physiol. Endrocrinol. Metab. 288, E1-E15 (2005).
9. Sabatine, MS, Liu, E, Morrow, DA, Heller, E, McCarroll, R, Wiegand, R, Berriz, GF, Roth, FP, Gerszten, RE. Metabolomic identification of novel biomarkers of myocardial ischaemia. Circulation 112, 3868-3875 (2005).
10. Rozen, S, Cudkowicz, ME, Bogdanov, M, Matson, WR, Kristal, BS, Beecher, C, Harrison, S, Vouros, P, Flarakos, J, Vigneau-Callahan, K, Matson, TD, Newhall, KM, Beal, F, Brown, RH, Kaddurah-Daouk, R. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1, 101-108 (2005).
11. Yaffe, K, Kanaya, A, Lindquist, K, Simonsick, EM, Harris, T, Shorr, RI, Tylavsky, FA, Newman, AB. The metabolic syndrome, inflammation, and the risk of cognitive decline. JAMA 292, 2237 (2004).
12. Garg, M, Bassilian, S, Bell, C, Lee, S, Lee, WNP. Hepatic de novo lipogenesis in stable low-birth-weight infants during exclusive breast milk feedings and during parenteral nutrition. J Parenter Enteral Nutr 29, 81-86 (2005).
13. Boros, LG, Serkova, NJ, Cascante, M, Lee, WN. Use of metabolic pathway flux information in targeted cancer drug design. Drug Discovery Today Therapeutic Strategies 1, 435-443 (2004).
14. Tollman, P, Guy, P, Altshuler, J, Flanagan, A, Steiner, M. A revolution in R&D: How genomics and genetics are transforming the biopharmaceutical industry. Boston Consulting Group, Boston, MA USA (2001) http://www.bcg.com/publications/files/ eng_genomicsgenetics_rep_11-01.pdf
15. Wheelock, CE, Schmelzer, K, Watkins, S, Hammock, BD, Newman, JW. Differential effects of a soluble epoxide hydrolase inhibitor and PPAR-alpha and -gamma agonists on mouse plasma lipid profiles. Poster presentation at Metabolomics 2005: The First Annual International Conference of the Metabolomics Society, Tsuruoka City, Japan, June 2005.
16. Harrigan, GG, Colca, JR, Szalma, S, Boros, LG. MitoNEET agonist PNU-91325 increases fatty acid synthesis from glucose and mitochondrial long chain fatty acid degradation; A comparative tracer-based metabolomics study with rosiglitazone and pioglitazone in HepG2 cells. Metabolomics, in press (2006).
17. Krul, E, Butteiger, D, Flickinger, A, Harrigan, GG, Wiest, MM, German, BG, Watkins, SM. Lipid metabolome analysis of the LDL receptor null mouse. Manuscript in preparation.
18. Davidov, E, Clish, CB, Oresic, M, Meys, M, Stochaj, W, Snell, P, Lavine, G, Londo,TR, Adourian, A, Zhang, X, Johnston, M, Morel, N, Marple, EW, Plasterer, TN, Neumann, E, Verheij, E, Vogels, JT, Havekes, LM, van der Greef, J, Naylor, S. Methods for the differential integrative omic analysis of plasma from a transgenic disease animal model. Omics 8, 267-288 (2004).
19. Griffin, JL, Bonney, SA, Mann, C, Hebbachi, AM, Gibbons, GF, Nicholson, JK, Shoulders, CC, Scott, J. An integrated reverse functional genomic and metabolic approach to understanding orotic acid induced fatty liver. Physiol Genomics 17, 140-149 (2004).
20. Harris, WS, von Schacky, C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med 39, 212-220 (2004).